Your session is about to expire
← Back to Search
LMWH + Aspirin vs. LMWH Alone for Preventing Blood Clots Post-partum (LEAP Trial)
LEAP Trial Summary
This trial is testing whether prophylactic anticoagulation with 3 weeks of LMWH followed by 3 weeks of Aspirin is better than the standard of care of prophylactic LMWH for 6 weeks at moderate to high risk of developing VTE.
LEAP Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowLEAP Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.LEAP Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a bleeding disorder.I have a genetic blood clotting disorder and a family history of blood clots.I am older than 18 years.I do not have any active bleeding except for normal menstrual bleeding.I have had very high blood pressure during or after my pregnancy.I have had blood clots without a clear cause or due to hormones and am not on blood thinners.My close family has a history of blood clot disorders.You cannot take aspirin because you are allergic to it, have had a stomach ulcer, or have a low platelet count during pregnancy or after giving birth.I am allergic to or cannot take LMWH.I need LMWH for an existing health condition.
- Group 1: Prophylactic Low Molecular Weight Heparin (LMWH)
- Group 2: Prophylactic Low Molecular Weight Heparin (LMWH) + Low Dose Aspirin
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals have enrolled in this experiment?
"Affirmative. According to the info posted on clinicaltrials.gov, this research project is actively searching for volunteers and has been since August 29th 2021 when it was first published. This study requires 50 participants from one site and was most recently updated on September 15th 2022."
What maladies typically benefit from the joint administration of low molecular weight heparin and low-dose aspirin?
"Low molecular weight heparin and low-dose aspirin are traditionally used to alleviate pain, but they can also mitigate the risk of peripheral arterial embolism, myocardial infarction, and catarrh."
Is enrollment for this experiment still available to participants?
"Affirmative. According to the information from clinicaltrials.gov, this medical investigation is still enrolling participants. This trial was first made available on August 29th 2021, and has been updated as recently as September 15th 2022. 50 patients will be admitted at one site for participation in the study."
What has been the outcome of prior investigations into Low molecular weight heparin and low-dose aspirin?
"Currently, 201 Low molecular weight heparin and low-dose aspirin studies are being conducted worldwide. Of those active trials, 60 have reached Phase 3 status. Although the majority of these experiments take place in Shanghai, there are 4156 sites executing research for this treatment."
Is this the inaugural implementation of such a trial?
"As of today, there are 201 active clinical trials involving Low molecular weight heparin and low-dose aspirin. These research projects span 60 countries and 1469 cities around the world. Since Abbott sponsored the initial trial in 2005 - which included 15480 participants and concluded Phase 4 drug approval - 688 studies have been completed."
Share this study with friends
Copy Link
Messenger